ABEO · Abeona Therapeutics Inc.

The appointment of Keith A. Goldan reflects Abeona’s deliberate effort to reinforce its Board with seasoned financial leadership during its transition to a commercial-stage biotech company, anchored by the recent launch of ZEVASKYN®. His background as CFO across multiple public biotech and specialty pharma firms — including leading capital raises, IPOs, M&A, and commercial infrastructure build-out — directly addresses stated strategic priorities around capital markets engagement, operational scaling, and financial stewardship. As newly designated Chair of the Audit Committee, his oversight role carries heightened significance given Abeona’s cGMP manufacturing operations, regulatory reporting obligations, and revenue recognition complexities associated with cell and gene therapy commercialization. The compensation structure — modest annual cash retainer paired with a time-vested equity grant — signals alignment with near-term execution milestones rather than long-term retention incentives, consistent with a newly appointed director joining mid-cycle ahead of the 2026 annual meeting. No related party transactions or governance exceptions were disclosed, preserving the independence and integrity of the appointment.